DATA GRAPHICS | Data Byte
Trodelvy label expansion could further boost Gilead cancer sales after $2.1B year
Still dwarfed by antivirals, cell therapy unit is key growth driver as Yescarta crosses blockbuster threshold
February 3, 2023 10:33 PM UTC
A new label expansion for Trodelvy figures to further drive sales growth in Gilead’s oncology business following a $2.1 billion year in 2022, making it the biopharma’s fastest-growing segment.
On Friday, FDA approved TROP2-targeting antibody-drug conjugate Trodelvy sacituzumab govitecan-hziy to treat hormone receptor-positive, HER2-negative breast cancer, expanding its label beyond prior approvals in triple-negative breast cancer and urothelial cancer. Sales of the drug in those indications reached $680 million in 2022, including $195 million in the year’s final quarter...
BCIQ Company Profiles